Through scientific innovation and collaboration, Boehringer Ingelheim is committed to discovering and developing novel anti-cancer agents that address unmet needs across a broad range of solid and hematological malignancies. Approved agents are for specific NSCLC sub-types and the oncology portfolio is supported by a strong early pipeline. As part of our unique research approach, we seek out strong partnerships and remain dedicated to delivering treatments that improve cancer patients’ lives.
900 Ridgebury Road
Ridgefield, Connecticut 06877